M

Middle East Pharmaceutical Industries Company SJSC
SAU:4016

Watchlist Manager
Middle East Pharmaceutical Industries Company SJSC
SAU:4016
Watchlist
Price: 121.2 SAR 1.68% Market Closed
Market Cap: 2.4B SAR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+15%
Revenue
Forecast
+12%
Operating Income
Forecast
0%
Net Income
Forecast
-9%

Wall Street
Price Targets

Price Targets Summary
Middle East Pharmaceutical Industries Company SJSC

Wall Street analysts forecast Middle East Pharmaceutical Industries Company SJSC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Middle East Pharmaceutical Industries Company SJSC is 133.62 SAR with a low forecast of 132.31 SAR and a high forecast of 137.55 SAR.

Lowest Forecast
Wall Street Target
132.31 SAR
9% Upside
Average Forecast
Wall Street Target
133.62 SAR
10% Upside
Highest Forecast
Wall Street Target
137.55 SAR
13% Upside
Lowest
Price Target
132.31 SAR
9% Upside
Average
Price Target
133.62 SAR
10% Upside
Highest
Price Target
137.55 SAR
13% Upside
Middle East Pharmaceutical Industries Company SJSC Competitors:
Price Targets
G
512
Grand Pharmaceutical Group Ltd
11% Upside
600557
Jiangsu Kanion Pharmaceutical Co Ltd
41% Upside
VRCA
Verrica Pharmaceuticals Inc
509% Upside
UCB
Ucb SA
19% Upside
G
512
Grand Pharmaceutical Group Ltd
11% Upside
600557
Jiangsu Kanion Pharmaceutical Co Ltd
41% Upside
VRCA
Verrica Pharmaceuticals Inc
509% Upside
UCB
Ucb SA
19% Upside
M
MANKIND
Mankind Pharma Ltd
18% Upside
H
13
HUTCHMED (China) Ltd
56% Upside
LAURUSLABS
Laurus Labs Ltd
10% Downside
4540
Tsumura & Co
25% Upside

Revenue
Forecast

Revenue Estimate
Middle East Pharmaceutical Industries Company SJSC

For the last 2 years the compound annual growth rate for Middle East Pharmaceutical Industries Company SJSC's revenue is 9%. The projected CAGR for the next 3 years is 15%.

9%
Past Growth
15%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Middle East Pharmaceutical Industries Company SJSC

For the last 2 years the compound annual growth rate for Middle East Pharmaceutical Industries Company SJSC's operating income is 4%. The projected CAGR for the next 3 years is 21%.

4%
Past Growth
21%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Middle East Pharmaceutical Industries Company SJSC

For the last 2 years the compound annual growth rate for Middle East Pharmaceutical Industries Company SJSC's net income is 0%. The projected CAGR for the next 3 years is 24%.

0%
Past Growth
24%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Middle East Pharmaceutical Industries Company SJSC's stock price target?
Price Target
133.62 SAR

According to Wall Street analysts, the average 1-year price target for Middle East Pharmaceutical Industries Company SJSC is 133.62 SAR with a low forecast of 132.31 SAR and a high forecast of 137.55 SAR.

What is Middle East Pharmaceutical Industries Company SJSC's Revenue forecast?
Projected CAGR
15%

For the last 2 years the compound annual growth rate for Middle East Pharmaceutical Industries Company SJSC's revenue is 9%. The projected CAGR for the next 3 years is 15%.

What is Middle East Pharmaceutical Industries Company SJSC's Operating Income forecast?
Projected CAGR
21%

For the last 2 years the compound annual growth rate for Middle East Pharmaceutical Industries Company SJSC's operating income is 4%. The projected CAGR for the next 3 years is 21%.

What is Middle East Pharmaceutical Industries Company SJSC's Net Income forecast?
Projected CAGR
24%

For the last 2 years the compound annual growth rate for Middle East Pharmaceutical Industries Company SJSC's net income is 0%. The projected CAGR for the next 3 years is 24%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 240,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.